Nanotherapies for the treatment of ocular diseases

S Reimondez-Troitiño, N Csaba, MJ Alonso… - European Journal of …, 2015 - Elsevier
The topical route is the most frequent and preferred way to deliver drugs to the eye.
Unfortunately, the very low ocular drug bioavailability (less than 5%) associated with this …

Critical appraisal of alternative irritation models: three decades of testing ophthalmic pharmaceuticals

H Abdelkader, B Pierscionek, M Carew… - British medical …, 2015 - academic.oup.com
Background Testing ocular tolerability of ocular pharmaceuticals is an essential regulatory
requirement. The current approved reference model (gold standard) for ocular irritation …

NIOSOMES AS APOTENTIAL CARRIER SYSTEM: A REVIEW.

J Keshav - … Journal of Pharmaceutical, Chemical & Biological …, 2015 - search.ebscohost.com
Niosomes are the non-ionic surfactant vesicles and like liposomes are bilayered structures,
which can entrap both hydrophilic and lipophilic drugs either in an aqueous layer or in …

[引用][C] Cell Toxicity and Ocular Tolerability of Chitosan Nanoparticles Loaded with OTZ

AA Al-Kinani, A Vangala, G Calabrese, B Pierscionek… - Cell